Top advances of the year: Small cell lung cancer
In 2024, therapeutic breakthroughs for small cell lung cancer have led to meaningful improvements for patients, offering potential for long-term survival. Here, the authors report the top advances fr…
Related Articles
Clinicopathological and molecular characterization of non–small cell lung cancer with pericardial effusions
Background Cytological evaluation is essential for assessing pericardial effusions (PEs) in non–small cell lung cancer (NSCLC). This study retrospectively examined the clinicopathological, molecular…
Germ cell and other tumors in individuals with differences in sex development
Approximately one in 3500 to one in 5100 live-born infants have atypical external genital development, known as differences in sex development (DSD). In 2005, an…
Glioma mutational signatures associated with haloalkane exposure are enriched in firefighters
By using whole-exome sequencing data from matched germline and tumor samples, the authors identify gliomas that had mutational signatures associated with haloalkane exposure and were…
Annual Report to the Nation on the Status of Cancer, featuring state‐level statistics after the onset of the COVID‐19 pandemic
The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate…
Update advances in anaplastic lymphoma kinase‐positive non–small cell lung cancer treatment
In this review, the authors summarize the diagnostic molecular testing for anaplastic lymphoma kinase (ALK) rearrangements, the update efficacy of novel ALK inhibitors, and future…
Comprehensive management of vulvovaginal cancers
Vulvar and vaginal cancers represent rare malignancies, with an incidence of 2.7 per 100,000 women for vulvar cancer, predominantly affecting women older than 60 years,…
Clinicopathological and molecular characterization of non–small cell lung cancer with pericardial effusions
Background Cytological evaluation is essential for assessing pericardial effusions (PEs) in non–small cell lung cancer (NSCLC). This study retrospectively examined the clinicopathological, molecular…
Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians
Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer-related death worldwide. Contemporary advances in systemic and locoregional therapies…
The emerging role of lymphocyte‐activation gene 3 targeting in the treatment of solid malignancies
Checkpoint inhibitors targeting the lymphocyte-activation gene 3 (LAG-3) pathway in combination with PD-1 blockade aim to provide similar efficacy and reduced toxicity than that of…
Current, persistent, and low‐poverty area residence and social risks among Black cancer survivors
This article evaluates the associations between area-level poverty concentration and social risks (e.g., food insecurity and housing instability) and financial hardship in a population-based cohort…